Apricus Biosciences Inc.'s erectile dysfunction drug Vitaros was approved for sale in Mexico.

Ferring Pharmaceuticals will market the drug on Apricus' behalf and paid the company $4.5 million in up-front payment as well as another $1.6 million in a regulatory milestone payment.

Apricus is eligible to receive up to a further $28 million in regulatory, launch and sales milestones, plus royalties on future net sales.

Vitaros is approved for use in more than 20 countries, including in parts of Europe.